What is the Neuronic x Phoenix photobiomodulation study?
The Neuronic x Phoenix study is an exclusive research partnership where APOE4 carriers in The Phoenix Community use a Neuronic transcranial photobiomodulation helmet to evaluate whether near-infrared light therapy supports brain health outcomes. Participants follow a structured protocol, track biomarkers and cognitive measures, and contribute data back to the community. The study gives members first access to a device and protocol that would otherwise require individual purchase and self-direction, and provides collective insights unavailable to single users.
How do APOE4 carriers enroll in the Neuronic Phoenix study?
Enrollment is exclusive to active members of The Phoenix Community. Members apply through the community, receive enrollment instructions from Dr. Kevin Tran and the Phoenix team, and arrange for the Neuronic helmet to be shipped to their home. Once the device arrives, members begin the protocol and log their sessions, adherence, and outcome measures through the Phoenix app. Cohort spots are limited, so interested APOE4 carriers should join the community first to secure access.
What is photobiomodulation and why does it matter for APOE4 carriers?
Photobiomodulation (PBM) uses red and near-infrared light to stimulate mitochondrial function and reduce neuroinflammation in brain tissue. For APOE4 carriers who face elevated Alzheimer disease risk driven in part by mitochondrial dysfunction and chronic inflammation, PBM represents a low-risk intervention with promising preclinical and early clinical data. The Neuronic helmet delivers targeted transcranial PBM, and the Phoenix study aims to gather APOE4-specific outcome data that generic PBM research does not provide.
